Canagliflozin has been proposed as an effective treatment for type 2 diabetes. This meta-analysis of randomized control trials aimed to evaluate the effect of canagliflozin combined with other hypoglycemic drugs.Materials and Methods:
We searched Medline, Embase, Cochrane Library, Google Scholar and ClinicalTrials.gov for randomized control trials comparing canagliflozin combined with conventional antidiabetic drugs vs placebo. Our main end-points were glycemic control and change in weight. We assessed pooled data by use of a random-effects model.Result:
Of 161 identified studies, six were eligible and were included in our analysis (n = 4670 participants). Compared with the placebo, mean changes in glycosylated hemoglobin were −0.60% (95% confidence interval −0.67 to −0.54%; I2 = 0%) for canagliflozin 100 mg, and −0.76% (95% confidence interval −0.84 to −0.68%; I2 = 20%) for canagliflozin 300 mg with bodyweight loss.Conclusion:
Canagliflozin as an add-on drug to other antidiabetic drugs effectively lowers blood glucose without significant weight gain.
Meta-analysis evaluated the effect of canagliflozin combined other antidiabetic drugs In accordance with the recommendation set forth in the PRISMA statement Both canagliflozin 100 mg-dose and 300 mg-dose evaluated.